Canaccord Genuity Maintains Buy on Boston Scientific, Lowers Price Target to $71

Benzinga Newsdesk www.benzinga.com Negative 61.6%

Neg 61.6% Neu 0% Pos 0%

Canaccord Genuity analyst William Plovanic maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $109 to $71.